Sun Pharma Advanced Research Company Limited

Sun Pharmaceutical Industries Limited

Trinadha Rao Chitturi

Rajamannar Thennati

Prabal Sengupta

Kanaksinh Jesingbhai Jadav

Gaurav Sanjivkumar Sheth

Bhavesh Mohanbhai Panchal

Jayraj Dilipbhai Aradhye

Jiten Ranchhodbhai Patel

Gopalkumar Chimanlal Patel

Sanjay Nandlalji Mandhane

Manoj Atmaramji Upadhya

Sameer Vishwanath Mehetre

Nitin Krishnaji Damle

Gajanan Uttamrao Chidrewar

Ranjan Kumar Pal

Hemant Ashvinbhai Chokshi

Sabbirhusen Yusufbhai Chimanwala

Sandeep Pankajbhai Pathak

Japan Nitinkumar Desai

Amit Pravinbhai Sedani

Kaushikkumar Dhanjibhai Prajapati

Dijixa Pinakin Rana

Indraneel Ghosh

Biswajit Samanta

Varun Anilkumar Mehta

Ajay Sohanlal Midha

Sanjay Nandlal Mandhane

V S N Murty Kadiyala

Dipali Manubhai Desai

Saikat Maity

Sairam V V M Kalapatapu

Samir Rameshchandra Shah

Chetan Surjitsingh Puri

Kamleshkumar Naranbhai Borkhataria

Shivramchandra Kanangi

Raja Sekhar Unnam

Rutvij Manharlal Bhatt

Vaibhav Jain

Vijaykumar Muljibhai Patel

Gulamnizami Abdulsattar Qureshi

Rajan Kumar Pal

Sudhakar Kambhampati

Hemant Ashvinbhai Shah

Tushar Mukund Jarag

Umesh Vishnu Chaudhari

Aishwarya Hampiholi

Sandeep Pankajkumar Pathak

Raj Gopal Venkat

Kaushik Dhanjibhai Prajapati

Jonathan David Atkinson

The invention relates to a method of treating or preventing Parkinson's disease in a subject comprising administering a compound of Formula I

Treatment for Parkinson's disease

The invention relates to a method of treating or preventing Parkinson's disease in a subject comprising administering a compound of Formula I 

The present invention provides novel heterocyclic compounds as anticancer agents, especially as estrogen receptor (ER) antagonists/degraders and process for their preparation.

Heterocyclic antiestrogens

The present invention relates to novel compounds useful as malic enzyme (ME) inhibitors, processes for their preparation and use of these compounds for the therapeutic treatment of disorders mediated by ME such as cancers (e.g. pancreatic ductal adenocarcinoma (PDAC)) in humans. The novel compounds have a structure according to Formula I or a pharmaceutically acceptable salt, stereoisomer or deuterated analog thereof, wherein X, R, Rand Y are as described herein.

Malic enzyme inhibitors

A selective estrogen receptor degrader (SERD), a compound 3-(3,5-difluorophenyl)-2-[4-[(E)-3-[3-(fluoromethyl)azetidin-1-yl]prop-1-enyl]phenyl]-4-methyl-2H-chromen-7-ol, and its S enantiomer, (2S)-3-(3,5-difluorophenyl)-2-[4-[(E)-3-[3-(fluoromethyl)azetidin-1-yl]prop-1-enyl]phenyl]-4-methyl-2H-chromen-7-ol, or pharmaceutically acceptable salts thereof. Also provided are processes for their preparation. Also provided for is the use of these compounds for the treatment of diseases which are related to modulation of estrogen receptors, such as ER-positive breast cancer.

Selective estrogen receptor degrader

Treatment of Parkinson's disease

The present invention relates to crystalline forms of S-[4-(3-fluoro-3-methylbutyryloxy)but-2-ynyl] 6&#x3b1;,9&#x3b1;-difluoro-17&#x3b1;-(furan-2-yl)carbonyloxy-11&#x3b2;-hydroxy-16&#x3b1;-methyl-3-oxoandrosta-1,4-diene-17&#x3b2;-carbothioate, an anti-inflammatory and anti-allergic glucocorticoid compound.

Crystalline forms of S-[4-(3-fluoro-3-methylbutyryloxy)but-2-ynyl] 6-&#x3b1;,9-&#x3b1;-difluoro-17-&#x3b1;-(furan-2-yl)carbonyloxy-11-&#x3b2;-hydroxy-16-&#x3b1;-methyl-3-oxoandrosta-1,4-diene-17-&#x3b2;-carbothioate

The present invention relates to novel diarylacetylene hydrazide compounds of formula (I) or pharmaceutically acceptable salt thereof, as tyrosine kinase inhibitors, the process for their preparation, and to the use of the compounds of formula (I) in the preparation of pharmaceutical compositions for the therapeutic treatment of disorders related to tyrosine kinases, in warm-blooded animals. 

Diarylacetylene hydrazide containing tyrosine kinase inhibitors

The invention provides 11&#x3b2;-hydroxyandrosta-4-ene-3-one compounds of Formula I, or physiologically acceptable salts or solvates thereof: wherein Rrepresents a moiety selected from a group consisting of (A), (B) and (C), with a proviso that when Rrepresents moiety (C), Z is S: 

11&#x3b2;-hydroxyandrosta-4-ene-3-ones

The present invention provides a process for preparing a compound of formula (I), or a pharmaceutically acceptable salt thereof, having the R-configuration, of formula (IA), or S-configuration of formula (IB), selectively over the other enantiomer. 

Process for the preparation of chiral beta amino carboxamide derivatives

The present invention relates to compounds of formula I or salts thereof, wherein, Ris selected from the group consisting of hydrogen and R; Ris selected from the group consisting of hydrogen, acetyl and R; Ris selected from the group consisting of alkyl, &#x2014;O-alkyl, &#x2014;NH-alkyl, aryl and heterocyclyl; Rrepresents a moiety (A) wherein, X is selected from the group consisting of a single bond, alkylene, alkenylene, alkynylene, arylene or a heterocyclylene moiety; Rand Rare same or different and are independently selected from hydrogen, alkyl, aryl or heterocyclyl; or Rand Rmay form together with the nitrogen atom to which they are attached a heterocyclyl ring system. 

Hydrazide containing taxane conjugates

The present invention provides substantially pure desloratadine having an HPLC purity greater than 99.5% and having an absorbance less than 0.15 Au at 420 nm for a 5% w/v solution in methanol, which does not show a peak for an impurity at a relative retention time in the range from about 0.85 to about 0.99 (relative to desloratadine appearing at a retention time of 25&#xb1;5 minutes), which is greater than the discard limit set at less than 0.025% of the total area, when tested according to an HPLC method performed using a Hypersil BDS Ccolumn (15 cm&#xd7;4.6 mm, 5 &#x3bc;m particle size) with the following parameters:  The present invention also provides a process for the preparation of substantially pure desloratadine by the process comprising acidic hydrolysis of a compound of formula 3 where R is selected from COR, COORwherein Ris selected from branched or linear alkyl (1-6 C), cycloalkyl, alkenyl, alkynyl, aryl, aralkyl and their substituted analogs; and their substituted analogs with a strong organic acid or a mineral acid. 

Process of preparing desaloratadine

The present invention provides a novel process for preparation of bisphosphonic acids or salts thereof, e.g. alendronic acid, by reacting a carboxylic acid, phosphorous acid and a halophosphorous compound in a water miscible neutral solvent.

Process for preparation of bisphosphonic acid compounds

A compound of formula I wherein X, Y, X' & Y&#x2032; are selected from hydrogen, halogen, substituted or unsubstituted alkyl (linear, branched or cyclo), aryl, alkyloxy and haloalkyl group; R, R, R& Rare selected from hydrogen, substituted or unsubstituted alkyl groups (linear, branched or cyclo), aryl, heteroaryl groups or aralkyl groups, heterocycles containing one or more of hetero atoms (viz., N, S, O), substituted or unsubstituted alkenyl or alkynyl groups of carbon 2 to 6; wherein the substituents R& Ron the piperazinyl moiety are either syn or anti to each other and optionally Rand Rtogether with the carbons to which they are attached form a monocyclic saturated or aryl or substituted aryl or heteroaryl or substituted heteroaryl ring containing one or more hetero atoms selected from N, S and O with a ring size ranging from 3 to 6; with a proviso that when R& Rtogether do not form part of a ring they may exist in either E or Z configuration; Ris (CH)&#x2014;O&#x2014;CH&#x2014;CO-Z wherein n is 1 to 6; Z is selected from OH, OR, NRR&#x2032;, N(OR)R&#x2032;, N(R)&#x2014;N(R)R&#x2032;and wherein R & R&#x2032; are selected from hydrogen, substituted or unsubstituted alkyl groups (linear, branched or cyclo), aryl, heteroaryl groups or aralkyl groups, heterocycles containing one or more of hetero atoms (viz., N, S, O), substituted or unsubstituted alkenyl or alkynyl groups of carbon 2 to 6; and B is selected from &#x2014;(CH)n-(n is 1 to 6) and &#x2014;(CH)x-D-(CH)y where D is O, NR, S or SO, x and y are independently 1 to 6; and m is selected from 1 to 6; and pharmaceutically acceptable salts thereof.

4-(diarylmethyl)-1-piperazinyl derivatives

Growing community of inventors

Baroda, India

Trinadha Rao Chitturi